英诺特: 北京市中伦律师事务所关于北京英诺特生物技术股份有限公司2023年限制性股票激励计划授予价格调整事项的法律意见书

Core Viewpoint - The legal opinion letter from Zhong Lun Law Firm confirms that Beijing Innotec Biotechnology Co., Ltd.'s 2023 restricted stock incentive plan has followed the necessary approval procedures and complies with relevant regulations [4][11]. Group 1: Approval Procedures - On August 27, 2023, the company's board of directors approved the draft of the 2023 restricted stock incentive plan and related proposals [4]. - The company held a temporary shareholders' meeting on September 14, 2023, where the incentive plan was approved [6]. - The company disclosed the list of incentive objects and their qualifications were verified by the supervisory board [5][7]. Group 2: Price Adjustment of Incentive Shares - The adjustment of the grant price for the restricted stock was necessitated by the company's dividend distribution plan, which involved a cash dividend of 5.60 yuan per 10 shares [9]. - The adjusted grant price for the restricted stock is calculated to be approximately 12.65 yuan per share after accounting for the dividend [9][10]. - The adjustment process was authorized by the shareholders' meeting and approved by the board of directors, thus complying with the relevant regulations [10][11].